HighTide Therapeutics Inc., a globally focused clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholang
September 27, 2018
Dr. Liping Liu, Founder & CEO of HighTide will present at the 25th Annual Future Leaders In The Biotech Industry on 23rd March 2018 in New York City. Dr. Liu will highlight HighTide’s product pipeline and development strategy. The...
March 20, 2018
HTD1801, one of HighTide’s lead candidates, awarded a grant in China as the ‘National Science and Technology Major Project’ for ‘New Drug Research and Development’ in November 2017....
March 01, 2018